Liraglutide for Low-responders After Bariatric Surgery

• Status: Withdrawn
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zuyderland Medisch Centrum
• Collaborator: Nederlandse Obesitas Kliniek
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• BMI before surgery was ≥ 35.0 kg/m2

• Patient is treated with group consultation at the NOK

• Patient has undergone a primary Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG)

• Patient is in the lowest %TWL quartile, 3 months after surgery and will be enrolled in the plus module.

Exclusion Criteria:

• Type 1 or type 2 diabetes

• Decreased renal function (creatinine clearance < 30 ml/min)

• Liver failure (all)

• Congestive heart failure or angina pectoris NYHA class III and IV

• Malignancy in history

• Pancreatitis (in history)

• Pregnancy / breast-feeding

• Inflammatory Bowel Disease

• Thyroid malignancy in history

• Use of warfarin or other coumarin derivates